MARKET

NTRA

NTRA

Natera Inc
NASDAQ
90.46
+0.46
+0.51%
Closed 19:30 03/27 EDT
OPEN
90.40
PREV CLOSE
90.00
HIGH
90.86
LOW
87.89
VOLUME
1.62M
TURNOVER
0
52 WEEK HIGH
96.24
52 WEEK LOW
36.90
MARKET CAP
10.92B
P/E (TTM)
-23.9249
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NTRA last week (0318-0322)?
Weekly Report · 3d ago
Natera: Capitalizing On The Positive Momentum Of Personalized Medicine
Natera Inc., a diagnostic company, focuses on women's health, oncology, and organ health. The global market for personalized medicines is estimated to reach $1,233.23 billion by 2033. Natera reported a 43% year-on-year increase in revenue in Q4 2023. The company is on the verge of becoming profitable for the first time in its history.
Seeking Alpha · 5d ago
Weekly Report: what happened at NTRA last week (0311-0315)?
Weekly Report · 03/18 09:27
Natera, Inc. Commented On The New KDIGO Guideline Supporting Genetic Testing For The Majority Of CKD Patients To Establish Cause Of Disease; Supports Broader Adoption Of Natera's Renasight Test
Supports broader adoption of Natera's RenasightTM test. The 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. The updated guideline supports the use of genetic testing to establish the cause of chronic kidney disease for a majority of patients with this condition.
Benzinga · 03/14 13:53
Bio-Techne and Qiagen had the biggest increase in short interest levels last month - Baird
Seeking Alpha · 03/13 18:01
Disney, Natera, Chubb And A Major Tech Stock On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Amy Raskin of Chevy Chase Trust said Natera, Inc. Can "go much higher" The Walt Disney Company is projected to have profitability in Disney+ by the end of September. ASML Holding N.V. Was named as a final trade.
Benzinga · 03/12 12:43
Weekly Report: what happened at NTRA last week (0304-0308)?
Weekly Report · 03/11 09:27
Natera Is Maintained at Overweight by Piper Sandler
Dow Jones · 03/06 14:43
More
About NTRA
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.

Webull offers Natera Inc stock information, including NASDAQ: NTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NTRA stock methods without spending real money on the virtual paper trading platform.